Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling

Previous studies have demonstrated that intravitreal delivery of brain-derived neurotrophic factor (BDNF) by injection of recombinant protein or by gene therapy can alleviate retinal ganglion cell (RGC) loss after optic nerve injury. BDNF gene therapy can improve RGC survival in experimental models...

Descripción completa

Detalles Bibliográficos
Autores principales: Osborne, Andrew, Khatib, Tasneem Z., Songra, Lalana, Barber, Amanda C., Hall, Katie, Kong, George Y. X., Widdowson, Peter S., Martin, Keith R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158290/
https://www.ncbi.nlm.nih.gov/pubmed/30258047
http://dx.doi.org/10.1038/s41419-018-1041-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158290/
https://www.ncbi.nlm.nih.gov/pubmed/30258047
http://dx.doi.org/10.1038/s41419-018-1041-8

Ejemplares similares